Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.

Individuals testing positive for human papillomavirus (HPV) had a 40% greater risk for overall cardiovascular disease (CVD) ...

Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Opthea in a report issued on Monday, ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

HC Wainwright raised their FY2025 EPS estimates for shares of Opthea in a note issued to investors on Tuesday, March 25th. HC ...

In this interview Prof. Dr. Kristina Kusche-Vihrog speaks about the nanomechanics of living cells and their implications for ...

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further ...

The following is a summary of “Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration,” published in the March 2025 issue of British Journal ...